Hill-Rom Holdings (NYSE: HRC) and CryoLife (NYSE:CRY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.
This table compares Hill-Rom Holdings and CryoLife’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Valuation & Earnings
This table compares Hill-Rom Holdings and CryoLife’s gross revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Hill-Rom Holdings has higher revenue and earnings than CryoLife. Hill-Rom Holdings is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and recommmendations for Hill-Rom Holdings and CryoLife, as reported by MarketBeat.
||Strong Buy Ratings
Hill-Rom Holdings currently has a consensus target price of $86.83, suggesting a potential upside of 7.92%. CryoLife has a consensus target price of $23.63, suggesting a potential upside of 18.13%. Given CryoLife’s stronger consensus rating and higher probable upside, analysts clearly believe CryoLife is more favorable than Hill-Rom Holdings.
Institutional and Insider Ownership
82.6% of Hill-Rom Holdings shares are owned by institutional investors. Comparatively, 68.4% of CryoLife shares are owned by institutional investors. 2.2% of Hill-Rom Holdings shares are owned by company insiders. Comparatively, 6.0% of CryoLife shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Hill-Rom Holdings has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, CryoLife has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.
Hill-Rom Holdings pays an annual dividend of $0.72 per share and has a dividend yield of 0.9%. CryoLife does not pay a dividend. Hill-Rom Holdings pays out 41.6% of its earnings in the form of a dividend. Hill-Rom Holdings has raised its dividend for 6 consecutive years and CryoLife has raised its dividend for 4 consecutive years.
Hill-Rom Holdings beats CryoLife on 10 of the 17 factors compared between the two stocks.
Hill-Rom Holdings Company Profile
Hill-Rom Holdings, Inc. is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions. The Company sells and rents its specialty frames and surfaces, and mobility solutions, as well as its clinical workflow solutions, in the United States and Canada through its North America Patient Support Systems segment, and in regions outside of the United States and Canada through its International Patient Support Systems segment. Its Front Line Care segment globally sells and rents respiratory care products, and sells medical diagnostic equipment and a diversified portfolio of devices that assess, diagnose, treat and manage a range of illnesses and diseases. Under its Surgical Solutions segment, the Company sells its surgical products globally.
CryoLife Company Profile
CryoLife, Inc. (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc. valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix. PhotoFix is a pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde. The Preservation Services segment includes external services, such as preservation of cardiac and vascular tissues. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch, both of which are processed using CryoLife’s SynerGraft technology.
Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.